CoChat
Sign Up
Cited by 746

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Cutaneous melanoma

Long, Georgina V, Swetter, Susan M, Menzies, Alexander M, Gershenwald, Jeffrey E, Scolyer, Richard A·2023·The Lancet
DOI 10.1016/s0140-6736(23)00821-8
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)00821-8

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 180

  1. Elder, 2020, The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway, Arch Pathol Lab Med, 144, 500, 10.5858/arpa.2019-0561-RA · DOI
  2. Berk-Krauss, 2020, New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986–2016, Am J Public Health, 110, 731, 10.2105/AJPH.2020.305567 · DOI
  3. Faries, 2017, Completion dissection or observation for sentinel-node metastasis in melanoma, N Engl J Med, 376, 2211, 10.1056/NEJMoa1613210 · DOI
  4. Leiter, 2019, Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node, J Clin Oncol, 37, 3000, 10.1200/JCO.18.02306 · DOI
  5. Cust, 2011, Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma, Int J Cancer, 128, 2425, 10.1002/ijc.25576 · DOI
  6. Chang, 2014, More skin, more sun, more tan, more melanoma, Am J Public Health, 104, e92, 10.2105/AJPH.2014.302185 · DOI
  7. Welch, 2021, The rapid rise in cutaneous melanoma diagnoses, N Engl J Med, 384, 72, 10.1056/NEJMsb2019760 · DOI
  8. Ferlay, 2021, Cancer statistics for the year 2020: an overview, Int J Cancer, 149, 778, 10.1002/ijc.33588 · DOI
  9. Whiteman, 2016, The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031, J Invest Dermatol, 136, 1161, 10.1016/j.jid.2016.01.035 · DOI
  10. Holman, 2018, Trends in melanoma incidence among non-Hispanic Whites in the United States, 2005 to 2014, JAMA Dermatol, 154, 361, 10.1001/jamadermatol.2017.5541 · DOI
  11. Aitken, 2018, Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995–2014, Int J Cancer, 142, 1528, 10.1002/ijc.31141 · DOI
  12. Iannacone, 2015, Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia, Int J Cancer, 136, 603, 10.1002/ijc.28956 · DOI
  13. Chen, 2022, Differences in thickness-specific incidence and factors associated with cutaneous melanoma in the US from 2010 to 2018, JAMA Oncol, 8, 755, 10.1001/jamaoncol.2022.0134 · DOI
  14. Gandini, 2005, Meta-analysis of risk factors for cutaneous melanoma: ii. Sun exposure, Eur J Cancer, 41, 45, 10.1016/j.ejca.2004.10.016 · DOI · Paper page
  15. Park, 2012, Risk factors for malignant melanoma in White and non-White/non-African American populations: the multiethnic cohort, Cancer Prev Res, 5, 423, 10.1158/1940-6207.CAPR-11-0460 · DOI
  16. Cho, 2005, Risk factors and individual probabilities of melanoma for Whites, J Clin Oncol, 23, 2669, 10.1200/JCO.2005.11.108 · DOI
  17. An, 2021, Indoor tanning and the risk of overall and early-onset melanoma and non-melanoma skin cancer: systematic review and meta-analysis, Cancers, 13, 10.3390/cancers13235940 · DOI
  18. Gandini, 2005, Meta-analysis of risk factors for cutaneous melanoma: i. Common and atypical naevi, Eur J Cancer, 41, 28, 10.1016/j.ejca.2004.10.015 · DOI
  19. Wei, 2019, Having a first-degree relative with melanoma increases lifetime risk of melanoma, squamous cell carcinoma, and basal cell carcinoma, J Am Acad Dermatol, 81, 489, 10.1016/j.jaad.2019.04.044 · DOI
  20. van der Leest, 2015, Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis, J Eur Acad Dermatol Venereol, 29, 1053, 10.1111/jdv.12887 · DOI
  21. Lee, 2010, Non-melanoma skin cancer and the risk of second primary cancers: a systematic review, Cancer Epidemiol Biomarkers Prev, 19, 1686, 10.1158/1055-9965.EPI-10-0243 · DOI
  22. Bliss, 1995, Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies, Int J Cancer, 62, 367, 10.1002/ijc.2910620402 · DOI
  23. Kubica, 2012, Melanoma in immunosuppressed patients, Mayo Clin Proc, 87, 991, 10.1016/j.mayocp.2012.04.018 · DOI
  24. Bradford, 2011, Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair, J Med Genet, 48, 168, 10.1136/jmg.2010.083022 · DOI · Paper page
  25. Bastian, 2014, The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia, Annu Rev Pathol, 9, 239, 10.1146/annurev-pathol-012513-104658 · DOI
  26. Arnold, 2018, Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012, Int J Cancer, 143, 1305, 10.1002/ijc.31527 · DOI
  27. Islami, 2018, Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, CA Cancer J Clin, 68, 31, 10.3322/caac.21440 · DOI · Paper page
  28. Keim, 2021, Cutaneous melanoma attributable to UVR exposure in Denmark and Germany, Eur J Cancer, 159, 98, 10.1016/j.ejca.2021.09.044 · DOI
  29. Nguyen, 2019, MITF and UV responses in skin: from pigmentation to addiction, Pigment Cell Melanoma Res, 32, 224, 10.1111/pcmr.12726 · DOI
  30. Wu, 2011, Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999–2006, J Am Acad Dermatol, 65, 26
  31. Whiteman, 2003, Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma, J Natl Cancer Inst, 95, 806, 10.1093/jnci/95.11.806 · DOI
  32. Guy, 2015, Vital signs: melanoma incidence and mortality trends and projections—United States, 1982–2030, MMWR Morb Mortal Wkly Rep, 64, 591
  33. Grossman, 2018, Behavioral counseling to prevent skin cancer: US Preventive Services Task Force recommendation statement, JAMA, 319, 1134, 10.1001/jama.2018.1623 · DOI
  34. Green, 2011, Reduced melanoma after regular sunscreen use: randomized trial follow-up, J Clin Oncol, 29, 257, 10.1200/JCO.2010.28.7078 · DOI · Paper page
  35. Bauer, 2011, BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site, Pigment Cell Melanoma Res, 24, 345, 10.1111/j.1755-148X.2011.00837.x · DOI · Paper page
  36. Curtin, 2005, Distinct sets of genetic alterations in melanoma, N Engl J Med, 353, 2135, 10.1056/NEJMoa050092 · DOI · Paper page
  37. Van Raamsdonk, 2009, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, 457, 599, 10.1038/nature07586 · DOI
  38. Viros, 2008, Improving melanoma classification by integrating genetic and morphologic features, PLoS Med, 5, e120, 10.1371/journal.pmed.0050120 · DOI
  39. Hayward, 2017, Whole-genome landscapes of major melanoma subtypes, Nature, 545, 175, 10.1038/nature22071 · DOI
  40. Newell, 2022, Comparative genomics provides etiological and biological insights into melanoma subtypes, Cancer Discov, 12, 2856, 10.1158/2159-8290.CD-22-0603 · DOI
  41. Newell, 2019, Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets, Nat Commun, 10, 10.1038/s41467-019-11107-x · DOI
  42. Shain, 2015, The genetic evolution of melanoma from precursor lesions, N Engl J Med, 373, 1926, 10.1056/NEJMoa1502583 · DOI
  43. Decatur, 2016, Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes, JAMA Ophthalmol, 134, 728, 10.1001/jamaophthalmol.2016.0903 · DOI
  44. McGovern, 1971, The classification of melanoma, Minn Med, 54, 426
  45. Zembowicz, 2011, Nevus/melanocytoma/melanoma: an emerging paradigm for classification of melanocytic neoplasms?, Arch Pathol Lab Med, 135, 300, 10.5858/2010-0146-RA.1 · DOI
  46. Broekaert, 2010, Genetic and morphologic features for melanoma classification, Pigment Cell Melanoma Res, 23, 763, 10.1111/j.1755-148X.2010.00778.x · DOI
  47. Murali, 2010, Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients, Cancer, 116, 4130, 10.1002/cncr.25148 · DOI
  48. Shain, 2015, Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway, Nat Genet, 47, 1194, 10.1038/ng.3382 · DOI
  49. Breitbart, 2012, Systematic skin cancer screening in Northern Germany, J Am Acad Dermatol, 66, 201, 10.1016/j.jaad.2010.11.016 · DOI
  50. Katalinic, 2015, Skin cancer screening in Germany: documenting melanoma incidence and mortality from 2008 to 2013, Dtsch Arztebl Int, 112, 629
  51. Boniol, 2015, Melanoma mortality following skin cancer screening in Germany, BMJ Open, 5, 10.1136/bmjopen-2015-008158 · DOI
  52. Waldmann, 2012, Skin cancer screening participation and impact on melanoma incidence in Germany—an observational study on incidence trends in regions with and without population-based screening, Br J Cancer, 106, 970, 10.1038/bjc.2012.22 · DOI
  53. 2023, Screening for skin cancer: US Preventive Services Task Force recommendation statement, JAMA, 329, 1290, 10.1001/jama.2023.4342 · DOI
  54. Gershenwald, 2017, Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 472, 10.3322/caac.21409 · DOI
  55. Ferris, 2017, A large skin cancer screening quality initiative: description and first-year outcomes, JAMA Oncol, 3, 1112, 10.1001/jamaoncol.2016.6779 · DOI
  56. Risica, 2018, Psychosocial consequences of skin cancer screening, Prev Med Rep, 10, 310, 10.1016/j.pmedr.2018.04.011 · DOI
  57. Aitken, 2010, Clinical whole-body skin examination reduces the incidence of thick melanomas, Int J Cancer, 126, 450, 10.1002/ijc.24747 · DOI
  58. McPherson, 2006, Presentation and detection of invasive melanoma in a high-risk population, J Am Acad Dermatol, 54, 783, 10.1016/j.jaad.2005.08.065 · DOI
  59. Moloney, 2014, Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study, JAMA Dermatol, 150, 819, 10.1001/jamadermatol.2014.514 · DOI
  60. Lo, 2020, The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan, Trials, 21, 594, 10.1186/s13063-020-04351-w · DOI
  61. Dinnes, 2018, Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults, Cochrane Database Syst Rev, 12
  62. Kaushal, 2020, Geographic distribution of US cohorts used to train deep learning algorithms, JAMA, 324, 1212, 10.1001/jama.2020.12067 · DOI · Paper page
  63. Young, 2021, Stress testing reveals gaps in clinic readiness of image-based diagnostic artificial intelligence models, NPJ Digit Med, 4, 10, 10.1038/s41746-020-00380-6 · DOI
  64. Kovarik, 2019, Commentary: position statement on augmented intelligence (AuI), J Am Acad Dermatol, 81, 998, 10.1016/j.jaad.2019.06.032 · DOI
  65. Scolyer, 2019, Improving diagnostic accuracy for suspicious melanocytic skin lesions: new Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication, Aust J Gen Pract, 48, 357, 10.31128/AJGP-11-18-4759 · DOI
  66. Wiesner, 2014, Kinase fusions are frequent in Spitz tumours and spitzoid melanomas, Nat Commun, 5, 10.1038/ncomms4116 · DOI
  67. Busam, 2014, Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions, Am J Surg Pathol, 38, 925, 10.1097/PAS.0000000000000187 · DOI
  68. Gerami, 2021, Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms, Mod Pathol, 34, 348, 10.1038/s41379-020-00658-w · DOI
  69. Yeh, 2019, Filigree-like rete ridges, lobulated nests, rosette-like structures, and exaggerated maturation characterize Spitz tumors with NTRK1 fusion, Am J Surg Pathol, 43, 737, 10.1097/PAS.0000000000001235 · DOI
  70. Lezcano, 2018, PRAME expression in melanocytic tumors, Am J Surg Pathol, 42, 1456, 10.1097/PAS.0000000000001134 · DOI
  71. Rawson, 2022, Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics, Pathology, 54, 863, 10.1016/j.pathol.2022.05.012 · DOI
  72. Morey, 2009, Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation, Pathology, 41, 383, 10.1080/00313020902915875 · DOI
  73. Benton, 2021, Impact of next-generation sequencing on interobserver agreement and diagnosis of Spitzoid neoplasms, Am J Surg Pathol, 45, 1597, 10.1097/PAS.0000000000001753 · DOI
  74. Grossman, 2020, Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit, JAMA Dermatol, 156, 1004, 10.1001/jamadermatol.2020.1729 · DOI
  75. Cerroni, 2010, Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008, Am J Surg Pathol, 34, 314, 10.1097/PAS.0b013e3181cf7fa0 · DOI
  76. Varey, 2023, Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: a systematic review and meta-analysis, J Eur Acad Dermatol Venereol, 37, 859, 10.1111/jdv.18665 · DOI
  77. Semsarian, 2022, Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?, Br J Dermatol, 186, 1030, 10.1111/bjd.21010 · DOI
  78. Elmore, 2017, Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study, BMJ, 357
  79. Frangos, 2012, Increased diagnosis of thin superficial spreading melanomas: a 20-year study, J Am Acad Dermatol, 67, 387, 10.1016/j.jaad.2011.10.026 · DOI
  80. Aivazian, 2021, Histological regression in melanoma: impact on sentinel lymph node status and survival, Mod Pathol, 34, 1999, 10.1038/s41379-021-00870-2 · DOI
  81. Scolyer, 2020, Melanoma pathology reporting and staging, Mod Pathol, 33, 15, 10.1038/s41379-019-0402-x · DOI
  82. Azimi, 2012, Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma, J Clin Oncol, 30, 2678, 10.1200/JCO.2011.37.8539 · DOI
  83. Garbe, 2022, European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment—update 2022, Eur J Cancer, 170, 256, 10.1016/j.ejca.2022.04.018 · DOI
  84. Swetter, 2019, Guidelines of care for the management of primary cutaneous melanoma, J Am Acad Dermatol, 80, 208, 10.1016/j.jaad.2018.08.055 · DOI
  85. Knackstedt, 2023, Differences in sentinel lymph node biopsy utilization in eligible melanoma patients treated with Mohs micrographic surgery or wide local excision: a population-based logistic regression model and survival analysis, J Am Acad Dermatol, 88, 848, 10.1016/j.jaad.2022.11.004 · DOI
  86. Robinson, 2020, Evidence-based clinical practice guidelines for the management of patients with lentigo maligna, Dermatology, 236, 111, 10.1159/000502470 · DOI
  87. Morton, 2014, Final trial report of sentinel-node biopsy versus nodal observation in melanoma, N Engl J Med, 370, 599, 10.1056/NEJMoa1310460 · DOI
  88. Gershenwald, 1999, Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients, J Clin Oncol, 17, 976, 10.1200/JCO.1999.17.3.976 · DOI
  89. Gannon, 2006, Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma, Cancer, 107, 2647, 10.1002/cncr.22320 · DOI
  90. Balch, 2014, Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients, Ann Surg Oncol, 21, 1075, 10.1245/s10434-013-3464-x · DOI
  91. Moncrieff, 2022, Evaluation of the indications for sentinel node biopsy in early-stage melanoma with the advent of adjuvant systemic therapy: an international, multicenter study, Ann Surg Oncol, 29, 5937, 10.1245/s10434-022-11761-4 · DOI
  92. Luke, 2022, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial, Lancet, 399, 1718, 10.1016/S0140-6736(22)00562-1 · DOI
  93. Long, 2022, Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial, Lancet Oncol, 23, 1378, 10.1016/S1470-2045(22)00559-9 · DOI
  94. Chai, 2012, Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma, Ann Surg Oncol, 19, 1100, 10.1245/s10434-011-2172-7 · DOI
  95. Dinnes, 2019, Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma, Cochrane Database Syst Rev, 7
  96. Lo, 2020, Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia nomogram, J Clin Oncol, 38, 2719, 10.1200/JCO.19.02362 · DOI
  97. Gershenwald, 2008, Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma, J Clin Oncol, 26, 4296, 10.1200/JCO.2007.15.4179 · DOI
  98. Murali, 2010, Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes, J Clin Oncol, 28, 4441, 10.1200/JCO.2010.30.9567 · DOI
  99. El Sharouni, 2021, Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas, J Clin Oncol, 39, 1243, 10.1200/JCO.20.02446 · DOI
  100. El Sharouni, 2021, Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data, Br J Surg, 108, 550, 10.1002/bjs.11946 · DOI
  101. Haydu, 2020, Cumulative incidence and predictors of CNS metastasis for patients with American Joint Committee on Cancer 8th edition stage III melanoma, J Clin Oncol, 38, 1429, 10.1200/JCO.19.01508 · DOI
  102. Cochran, 2022, Sentinel lymph node melanoma metastases: assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I), Eur J Surg Oncol, 48, 1280, 10.1016/j.ejso.2022.01.021 · DOI
  103. Eggermont, 2020, Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model, Eur J Cancer, 140, 11, 10.1016/j.ejca.2020.08.029 · DOI
  104. Gastman, 2019, Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria, J Am Acad Dermatol, 80, 149, 10.1016/j.jaad.2018.07.028 · DOI
  105. Dummer, 2020, Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial, Lancet Oncol, 21, 358, 10.1016/S1470-2045(20)30062-0 · DOI
  106. Lee, 2018, Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma, Ann Oncol, 29, 490, 10.1093/annonc/mdx717 · DOI
  107. Long, 2022, Association of pre-treatment ctDNA and other clinical and translational factors with disease recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915), Ann Oncol, 33, S356
  108. Broman, 2021, Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2), Cancer, 127, 2251, 10.1002/cncr.33483 · DOI
  109. Menzies, 2021, Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), Nat Med, 27, 301, 10.1038/s41591-020-01188-3 · DOI
  110. Amaria, 2019, Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium, Lancet Oncol, 20, e378, 10.1016/S1470-2045(19)30332-8 · DOI
  111. Ives, 2017, Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis, Eur J Cancer, 82, 171, 10.1016/j.ejca.2017.06.006 · DOI
  112. Eggermont, 2015, Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, Lancet Oncol, 16, 522, 10.1016/S1470-2045(15)70122-1 · DOI · Paper page
  113. Eggermont, 2016, Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy, N Engl J Med, 375, 1845, 10.1056/NEJMoa1611299 · DOI
  114. Ascierto, 2020, Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial, Lancet Oncol, 21, 1465, 10.1016/S1470-2045(20)30494-0 · DOI · Paper page
  115. Weber, 2023, Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915), J Clin Oncol, 41, 517, 10.1200/JCO.22.00533 · DOI
  116. Eggermont, 2020, Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial, J Clin Oncol, 38, 3925, 10.1200/JCO.20.02110 · DOI
  117. Eggermont, 2021, Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, Lancet Oncol, 22, 643, 10.1016/S1470-2045(21)00065-6 · DOI
  118. Eggermont, 2022, Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma, NEJM Evid, 1, 10.1056/EVIDoa2200214 · DOI
  119. Long, 2017, Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, N Engl J Med, 377, 1813, 10.1056/NEJMoa1708539 · DOI
  120. Dummer, 2020, Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma, N Engl J Med, 383, 1139, 10.1056/NEJMoa2005493 · DOI
  121. Khattak MA, Carlino M, Meniawy T, et al. A personalized cancer vaccine, mRNA-4157 (V940), combined with pembrolizumab alone in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201/KEYNOTE-942 trial. American Association for Cancer Research Annual Meeting 2023; Apr 14–19, 2023 (oral presentation CT001). · DOI · Paper page
  122. Long, 2023, Neoadjuvant checkpoint immunotherapy and melanoma: the time is now, J Clin Oncol
  123. Grossmann, 2022, Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma, Cancer Discov, 12, 644, 10.1158/2159-8290.CD-21-1141 · DOI
  124. Livingstone, 2022, Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial, Lancet, 400, 1117, 10.1016/S0140-6736(22)01654-3 · DOI
  125. Tetzlaff, 2018, Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma, Ann Oncol, 29, 1861, 10.1093/annonc/mdy226 · DOI
  126. Blank, 2018, Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma, Nat Med, 24, 1655, 10.1038/s41591-018-0198-0 · DOI · Paper page
  127. Huang, 2019, A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma, Nat Med, 25, 454, 10.1038/s41591-019-0357-y · DOI
  128. Long, 2019, Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial, Lancet Oncol, 20, 961, 10.1016/S1470-2045(19)30331-6 · DOI
  129. Amaria, 2022, Neoadjuvant relatlimab and nivolumab in resectable melanoma, Nature, 611, 155, 10.1038/s41586-022-05368-8 · DOI
  130. Rozeman, 2021, Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma, Nat Med, 27, 256, 10.1038/s41591-020-01211-7 · DOI
  131. Reijers, 2022, Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial, Nat Med, 28, 1178, 10.1038/s41591-022-01851-x · DOI
  132. Robert, 2020, Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma, J Clin Oncol, 38, 3937, 10.1200/JCO.20.00995 · DOI
  133. Burmeister, 2012, Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial, Lancet Oncol, 13, 589, 10.1016/S1470-2045(12)70138-9 · DOI
  134. Henderson, 2015, Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial, Lancet Oncol, 16, 1049, 10.1016/S1470-2045(15)00187-4 · DOI
  135. Flaherty, 2013, Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma, J Clin Oncol, 31, 373, 10.1200/JCO.2012.42.1529 · DOI
  136. Hersh, 2015, A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma, Ann Oncol, 26, 2267, 10.1093/annonc/mdv324 · DOI
  137. Robert, 2019, Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study, Lancet Oncol, 20, 1239, 10.1016/S1470-2045(19)30388-2 · DOI · Paper page
  138. Wolchok, 2022, Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma, J Clin Oncol, 40, 127, 10.1200/JCO.21.02229 · DOI
  139. Long, 2014, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, 371, 1877, 10.1056/NEJMoa1406037 · DOI
  140. Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 19, 603, 10.1016/S1470-2045(18)30142-6 · DOI
  141. Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI
  142. Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 · DOI
  143. Ascierto, 2021, 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study, Clin Cancer Res, 27, 5225, 10.1158/1078-0432.CCR-21-0809 · DOI
  144. Dummer, 2022, COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma, J Clin Oncol, 40, 4178, 10.1200/JCO.21.02659 · DOI
  145. Franklin, 2023, Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG, J Immunother Cancer, 11, 10.1136/jitc-2022-005828 · DOI
  146. Schadendorf, 2015, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma, J Clin Oncol, 33, 1889, 10.1200/JCO.2014.56.2736 · DOI · Paper page
  147. Maio, 2015, Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial, J Clin Oncol, 33, 1191, 10.1200/JCO.2014.56.6018 · DOI
  148. Ascierto, 2017, Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 18, 611, 10.1016/S1470-2045(17)30231-0 · DOI
  149. Lebbé, 2019, Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial, J Clin Oncol, 37, 867, 10.1200/JCO.18.01998 · DOI · Paper page
  150. Long, 2017, Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, Lancet Oncol, 18, 1202, 10.1016/S1470-2045(17)30428-X · DOI
  151. Tawbi, 2022, Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma, N Engl J Med, 386, 24, 10.1056/NEJMoa2109970 · DOI
  152. Ascierto, 2023, Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial, J Clin Oncol, 41, 212, 10.1200/JCO.21.02961 · DOI
  153. Atkins, 2023, Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134, J Clin Oncol, 41, 186, 10.1200/JCO.22.01763 · DOI
  154. Long, 2018, Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases:a multicentre randomised phase 2 study, Lancet Oncol, 19, 672, 10.1016/S1470-2045(18)30139-6 · DOI
  155. Tawbi, 2018, Combined nivolumab and ipilimumab in melanoma metastatic to the brain, N Engl J Med, 379, 722, 10.1056/NEJMoa1805453 · DOI
  156. D'Angelo, 2017, Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis, J Clin Oncol, 35, 226, 10.1200/JCO.2016.67.9258 · DOI
  157. Dimitriou, 2022, Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study, Ann Oncol, 33, 968, 10.1016/j.annonc.2022.06.004 · DOI
  158. Pires da Silva, 2022, Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma, J Clin Oncol, 40, 1068, 10.1200/JCO.21.01701 · DOI
  159. Ascierto, 2023, Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study, Lancet Oncol, 24, 33, 10.1016/S1470-2045(22)00687-8 · DOI
  160. Dummer, 2022, Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAFV600-mutant unresectable or metastatic melanoma, J Clin Oncol, 40, 1428, 10.1200/JCO.21.01601 · DOI
  161. Dummer, 2022, Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol, 23, 1145, 10.1016/S1470-2045(22)00452-1 · DOI
  162. Olson, 2021, Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma, J Clin Oncol, 39, 2647, 10.1200/JCO.21.00079 · DOI
  163. Friedman, 2022, Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses, J Immunother Cancer, 10, 10.1136/jitc-2021-003853 · DOI
  164. Pires da Silva, 2021, Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study, Lancet Oncol, 22, 836, 10.1016/S1470-2045(21)00097-8 · DOI
  165. Vanderwalde AM, Moon J, Kendra K, et al. Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. 2022 AACR Annual Meeting; April 8–13, 2022 (abstr CT013). · DOI
  166. Menzies, 2022, CTLA-4 blockade resistance after relatlimab and nivolumab, N Engl J Med, 386, 1668, 10.1056/NEJMc2119768 · DOI
  167. Newell, 2022, Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance, Cancer Cell, 40, 88, 10.1016/j.ccell.2021.11.012 · DOI
  168. Ch'ng, 2021, Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies, Eur J Cancer, 153, 8, 10.1016/j.ejca.2021.04.037 · DOI
  169. Liniker, 2016, Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma, OncoImmunology, 5, 10.1080/2162402X.2016.1214788 · DOI
  170. Tawbi, 2021, Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study, Lancet Oncol, 22, 1692, 10.1016/S1470-2045(21)00545-3 · DOI
  171. Long, 2021, Five-year overall survival from the anti-PD1 brain collaboration (ABC study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets), J Clin Oncol, 39
  172. Davies, 2017, Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, Lancet Oncol, 18, 863, 10.1016/S1470-2045(17)30429-1 · DOI
  173. Tawbi, 2021, Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204), Neuro-oncol, 23, 1961, 10.1093/neuonc/noab094 · DOI
  174. Martin, 2018, Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation, JAMA Oncol, 4, 1123, 10.1001/jamaoncol.2017.3993 · DOI
  175. Pires da Silva, 2019, Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies, Pigment Cell Melanoma Res, 32, 553, 10.1111/pcmr.12775 · DOI
  176. Andtbacka, 2019, Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma, J Immunother Cancer, 7, 145, 10.1186/s40425-019-0623-z · DOI
  177. Rohaan, 2022, Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma, N Engl J Med, 387, 2113, 10.1056/NEJMoa2210233 · DOI
  178. Sarnaik, 2022, Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study), J Immunother Cancer, 10, A820
  179. Ascierto, 2023, Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial, J Clin Oncol, 10.1200/JCO.22.02072 · DOI
  180. Arance, 2023, Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination, J Clin Oncol, 41, 75, 10.1200/JCO.22.00221 · DOI

Cited by

Sorted by citations

See all 746

Metadata

Authors
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-08
Volume
402
Issue
10400
Pages
485-502
ISSN
0140-6736
DOI
10.1016/s0140-6736(23)00821-8
Cited by
746
References
22
Language
en
Update notices
erratum (2023-08-05)
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review